Print
|
Close
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/?or Midline Gliomas
Active:
Yes
Cancer Type:
Brain Tumor
NCT ID:
NCT04617002
Trial Phases:
Protocol IDs:
ONC028 (primary)
Eligibility:
, Male and Female
Study Type:
Study Sponsor:
Chimerix
NCI Full Details:
Summary
This is an intermediate-size expanded access protocol to provide ONC201 (dordaviprone) to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 (dordaviprone) through clinical trials.
Treatment Sites in Georgia
University Cancer and Blood Center, LLC - Athens Medical Oncology
3320 Old Jefferson Road
Building 800
Athens, GA 30607
www.universitycancer.com
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.